Tag Archive for: Collaboration

DelSiTech and Tolmar Announce Global License and Development Agreement

Tolmar secures global license to DelSiTech’s Silica Matrix technology to develop and commercialize two undisclosed drug targets DelSiTech and Tolmar to expand development of additional drug products across a range of therapeutic areas DelSiTech is eligible to receive upfront payments, development and commercial milestone payments, and royalties on licensed products Turku, Finland and Dublin, Ireland […]

Futura Medical extends collaboration with Cooper Consumer Health

Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), the pharmaceutical company developing innovative sexual health products, today announces that it has extended until January 2029 its exclusive licensing agreement with Cooper Consumer Health (“Cooper”), a leading European independent self-care organisation, for the rights to commercialise Eroxon®, the Company’s topical, gel-based Erectile Dysfunction (“ED”) treatment, throughout the European […]

Poolbeg Pharma Partners with a Nasdaq-Listed Biopharma Company on its Oral Delivery Platform

Strategic collaboration focussed on the development of an optimised drug for a metabolic condition using Poolbeg’s licensed oral delivery technology Collaboration may expand to a full licensing agreement 17 October 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that it has signed a […]

ISA Pharmaceuticals to Present Pre-clinical Data on its Protective SLP Therapy Against SARS-CoV-2 at the CIMT Annual Meeting

Oegstgeest, The Netherlands, 27 April 2023 – ISA Pharmaceuticals, B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, is pleased to announce that it will be presenting data evaluating the response to its T cell inducing SLP therapy against SARS-CoV-2 in collaboration with the Leiden University Medical Center (LUMC) and […]

Aldena Therapeutics and Empa Awarded InnoSuisse Funding to Advance STAR Particles as a Novel Drug Delivery Technology for Dermatology

Boston, Massachusetts, April 26, 2023 – Aldena Therapeutics Inc. (Aldena), a private biotech company pioneering siRNA-based therapies for dermatological indications, and Empa, the Swiss Federal research institute for materials science and technology, have been awarded a joint 600’000 CHF grant by InnoSuisse, the Swiss Innovation Agency. This StarCURE grant seeks to co-develop microneedle particles as […]